hNPC 01
Alternative Names: hNPC-01Latest Information Update: 12 Mar 2024
At a glance
- Originator Hopstem Biotechnology
- Class Induced pluripotent stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Stroke
- Research Cerebral palsy; Traumatic brain injuries
Most Recent Events
- 09 Nov 2023 Phase-I clinical trials in Stroke in China (Intracerebral) (NCT06299033)
- 02 Nov 2021 Hopstem Biotechnology plans phase I trials for Traumatic brain injury and Cerebral palsy in first second half of 2022 (Hopstem Biotechnology pipeline, November 2021)
- 31 Oct 2021 Hopstem Biotechnology plans to file IND application for Stroke in USA and China